Analyzing MiNK Therapeutics (NASDAQ:INKT) & Achilles Therapeutics (NASDAQ:ACHL)

MiNK Therapeutics (NASDAQ:INKT) and Achilles Therapeutics (NASDAQ:ACHL) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, profitability, risk, analyst recommendations, dividends, institutional ownership and valuation.

Risk and Volatility

MiNK Therapeutics has a beta of 0.17, indicating that its stock price is 83% less volatile than the S&P 500. Comparatively, Achilles Therapeutics has a beta of 1.32, indicating that its stock price is 32% more volatile than the S&P 500.

Insider and Institutional Ownership

2.9% of MiNK Therapeutics shares are owned by institutional investors. Comparatively, 56.4% of Achilles Therapeutics shares are owned by institutional investors. 20.6% of MiNK Therapeutics shares are owned by company insiders. Comparatively, 5.4% of Achilles Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Profitability

This table compares MiNK Therapeutics and Achilles Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
MiNK Therapeutics	N/A	N/A	-189.14%
Achilles Therapeutics	N/A	-54.45%	-47.68%

Earnings & Valuation

This table compares MiNK Therapeutics and Achilles Therapeutics”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MiNK Therapeutics	N/A	N/A	-$22.46 million	($3.90)	-2.85
Achilles Therapeutics	N/A	N/A	-$69.67 million	($1.65)	-0.84

MiNK Therapeutics is trading at a lower price-to-earnings ratio than Achilles Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current ratings and recommmendations for MiNK Therapeutics and Achilles Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MiNK Therapeutics	0	0	2	0	3.00
Achilles Therapeutics	0	1	1	0	2.50

MiNK Therapeutics currently has a consensus target price of $65.00, suggesting a potential upside of 484.53%. Achilles Therapeutics has a consensus target price of $4.00, suggesting a potential upside of 188.81%. Given MiNK Therapeutics’ stronger consensus rating and higher possible upside, equities research analysts plainly believe MiNK Therapeutics is more favorable than Achilles Therapeutics.

Summary

MiNK Therapeutics beats Achilles Therapeutics on 6 of the 11 factors compared between the two stocks.

About MiNK Therapeutics

MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. The company was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.

About Achilles Therapeutics

Achilles Therapeutics plc, a biopharmaceutical company, develops precision T cell therapies to treat solid tumors. Its platform identifies mutations formed early in the development of cancer. The company offers PELEUS, a proprietary AI-powered bioinformatics platform, used to identify clonal neoantigens in a patient. It also develops CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. Achilles Therapeutics Plc was founded in 2016 and is headquartered in London, the United Kingdom.